> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# 6 Goals in CBER Strategic Plan
- URL: https://www.fdaweb.com/6-goals-in-cber-strategic-plan/
- Published: 2016-10-18T12:00:00.000Z
- Updated: 2026-09-14T21:40:20.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5137107

The Center for Biologics Evaluation and Research interim strategic [plan](http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CBER/UCM266867.pdf?ref=fdaweb.com) for 2017-2019 includes five overarching program goals and a sixth cross-cutting goal. Center director **Peter Marks** identifies the goals as: 

- increase the nation’s preparedness to address threats as a result of terrorism, pandemic influenza, and emerging infectious diseases;
- improve global public health through international collaboration including research and information sharing;
- use advances in science and technology to facilitate development of safe and effective biological products;
- ensure the safety of biological products;
- advance regulatory science and research; and
- manage for organizational excellence and accountability.

“We view this strategic plan as a living document that will allow is to modify our direction and approach as new regulatory challenges, obligations, and opportunities to serve the public’s health emerge,” Marks writes. The plan extends the CBER 2012-2016 strategic plan for two years, to carry the Center through establishment of new HHS and FDA strategic plans in 2018\. The document contains objectives and strategies for each of the six goals.